Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Occurrence of new cancers after rituximab treatment for patients with diffuse large B-cell lymphoma

Posted by on Aug 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors examined whether rituximab was associated with the development of a second cancer after treatment for diffuse large B-cell lymphoma. The authors concluded that the number of patients with certain cancers has increased after rituximab was introduced. Some background Diffuse large B-cell lymphoma (DLBCL) is a very...

Read More

The use of rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma

Posted by on Aug 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors looked at the effect of rituximab (Rituxan) treatment after autologous stem cell transplantation in patients with mantle cell lymphoma. The authors concluded that the use of rituximab after autologous stem cell transplantation improves outcomes for patients with mantle cell lymphoma.  Some background Mantle cell...

Read More

Long term outcomes for patients with advanced follicular lymphoma treated with FCM chemotherapy

Posted by on Aug 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors looked at the long-term outcomes for patients with advanced follicular lymphoma when treated with fludaranine, cyclophosphamide, and mitoxantrone (FCM). The authors concluded that FCM leads to long-lasting response with low rates of negative effects. Some background Follicular lymphoma (FL) is effectively treated with...

Read More

Influence of weight on survival for patients with indolent and mantle cell non-Hodgkin lymphoma

Posted by on Jul 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examines the effect of body mass index (BMI, a measure of body fat that takes height and weight into account) on the survival of patients with indolent and mantle cell lymphomas. The authors concluded that BMI affects the overall survival of patients with indolent and mantle cell lymphoma.  Some background Obesity is...

Read More

Risks and outcomes of relapse in patients with diffuse large B-cell lymphoma

Posted by on Jul 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the difference between early and late relapses in patients with diffuse large B-cell lymphoma. The authors concluded that patients who experience a late relapse have better outcomes than those who experience early relapse. Some background Diffuse large B-cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma. It...

Read More

Leukemia, CAR T-cell Therapy and Dr. Larry

Leukemia, CAR T-cell Therapy and Dr. Larry

Posted by on Jul 27, 2017 in Blog, Hodgkin's lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin lymphoma | 0 comments

Marathons are grueling 26.2 mile treks.  The Boston Marathon is the oldest (started in 1897) and is one of the Marathon Majors (along with London, New York, Tokyo, Berlin and Chicago). Marathon Man Raising Money For LLS In 2001, at age 48,  family practitioner, Larry Saltzman ran his first marathon in Chicago.  That started a  13 marathon odyssey to...

Read More

What are the long-term effects in adult survivors of childhood non-Hodgkin lymphoma?

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study explored the long-term health outcomes of adult survivors of childhood non-Hodgkin lymphoma (NHL) patients. The authors determined that adult survivors have a high rate of chronic health conditions. Some background Long-term survival of childhood NHL has increased due to improvements in treatment options. An understanding...

Read More

Stem cell transplantation in follicular lymphoma

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reviewed the use of stem cell (immature blood cell) transplantation in follicular lymphoma. Some background New treatment options have improved survival in follicular lymphoma patients. Improvements in stem cell transplantation (SCT) have also led to increased survival. Typically only younger patients have been able to...

Read More

Combining bendamustine and rituximab improves time to disease progression in follicular and mantle-cell lymphomas

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the use of the combination of bendamustine (Treanda) and rituximab (Rituxan) as a firstline treatment in patients with follicular or mantle cell lymphoma. This study concluded that this treatment combination was more effective than the standard treatment of rituximab plus CHOP chemotherapy. Some background The...

Read More

Is ibrutinib effective as a first-line therapy in B-cell non-Hodgkin lymphoma?

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the use of ibrutinib (Imbruvica) combined with the chemotherapy combination R-CHOP in untreated diffuse large B-cell lymphoma. This study determined that ibrutinib was safe and effective when added to R-CHOP. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is a...

Read More